Acta Cardiol Sin 33(5): 461-467

The Role of Endoglin in Myocardial Fibrosis

Division of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.

Dr. Kou-Gi Shyu, Division of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen-Chang Road, Shin Lin, Taipei 111, Taiwan. Tel: 886-2-2833-2211; Fax: 886-2-2836-5775; ten.tenih.21sm@gkuyhS

Division of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.

Dr. Kou-Gi Shyu, Division of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wen-Chang Road, Shin Lin, Taipei 111, Taiwan. Tel: 886-2-2833-2211; Fax: 886-2-2836-5775; ten.tenih.21sm@gkuyhS

Received 2017 Jan 10; Accepted 2017 Feb 21.

Abstract

Myocardial fibrosis is closely associated with heart failure because myocardial fibrosis may cause the loss of normal cardiac function. Endoglin is a homeodimeric membrane glycoprotein, a co-receptor of transforming growth factor-β1 (TGF-β1) and β3. Endoglin is a potent mediator of profibrotic effects of angiotensin II on cardiac fibroblasts and can modulate the effect of TGF-β1 on extracellular matrix synthesis. These data indicate that endoglin plays an important role in fibrogenesis in cardiac remodeling. Endoglin induced by TGF-β1 is largely through PI-3 kinase, Akt, Smad3/4 and endoglin promoter pathways. Endoglin was upregulated in pressure- overload, volume-overload heart failure and acute myocardial infarction and was associated with myocardial fibrosis. Silencing endoglin expression could attenuate myocardial fibrosis and improve survival in animal study. Endoglin expression was increased in failing left ventricle before use of left ventricle assist device, and reduced back to control levels after use of left ventricle assist device. Targeting endoglin may provide a potentially unique and novel therapeutic approach for reducing myocardial fibrosis in patients with heart failure.

Keywords: Angiotensin II, Endoglin, MicroRNA, Myocardial fibrosis, TGF-β1

Abstract

CONFLICT OF INTERESTS

None to declare.

CONFLICT OF INTERESTS

REFERENCES

References

1. Aronow WSEpidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev. 2006;14:108–124.[PubMed][Google Scholar]
2. Mozaflarian D, Benzamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update. A report from the American Heart Association. Circulation. 2016;133:e38–e360.[PubMed]
3. Berk BC, Fujiwara K, Lehoux SECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568–575.[Google Scholar]
4. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation. 2000;101:2981–2988.[PubMed]
5. Swynghedauw BMolecular mechanisms of myocardial remodeling. Phys Rev. 1999;79:215–262.[PubMed][Google Scholar]
6. Benjamin IJTargeting endoglin, an auxiliary TGF-β coreceptor, to prevent fibrosis and heart failure. Circulation. 2012;125:2689–2691.[Google Scholar]
7. Lijnen PJ, Petrov VV, Fagard RHInduction of cardiac fibrosis by transforming growth factor-β1. Mol Genetic Metabol. 2000;71:418–435.[PubMed][Google Scholar]
8. Kuwahara F, Kai H, Tokuda K, et al Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130–135.[PubMed][Google Scholar]
9. Lim H, Zhu YZRole of transforming growth factor-β in the progression of heart failure. Cell Mol Life Sci. 2006;63:2584–2596.[PubMed][Google Scholar]
10. Fonsatti E, Altomonte M, Arslan P, Maio MEndoglin (CD105): a target for anti-angiogenic cancer therapy. Curr Drug Targets. 2003;4:291–296.[PubMed][Google Scholar]
11. Van de Driesche S, Mummery CL, Wetermann CJHereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res. 2003;58:20–31.[PubMed][Google Scholar]
12. Duff SE, Li C, Garland JM, Kumar SCD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003;17:984–992.[PubMed][Google Scholar]
13. Guttmacher AE, Marchuk DA, White RI., JrHereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918–924.[PubMed][Google Scholar]
14. McAllister KA, Grogg KM, Johnson DW, et al Endoglin, a TGF-beta binding protein of endothelial cells, is the gen for hereditary hemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345–351.[PubMed][Google Scholar]
15. Li DY, Sorensen LK, Brooke BS, et al Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534–1517.[PubMed][Google Scholar]
16. Bourdeau A, Dumont DJ, Letarte MA murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999;104:1343–1351.[Google Scholar]
17. St-Jacques S, Cymerman U, Pece N, Letarte MMolecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stroma cells. Endocrinology. 1994;134:2645–2657.[PubMed][Google Scholar]
18. Kapur NK, Wilson S, Yunis AA, et al Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012;125:2728–2738.[Google Scholar]
19. Valeria B, Maddalena G, Entrica V, et al Endoglin (CD105) expression in the human heart through gestation: an immunohistochemical study. Reprod Sci. 2008;15:1018–1026.[PubMed][Google Scholar]
20. Hawinkels LJ, Kuiper P, Wiercinska E, et al Matrix metalloproteinase-14 (MT1-MMP)-induced endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010;70:4141–4150.[PubMed][Google Scholar]
21. Chen K, Mehta JL, Li D, et al Transforming growth factor-β receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res. 2004;95:1167–1173.[PubMed][Google Scholar]
22. Rodríguez-Barbero A, Obreo J, Alvarez-Munoz P, et al Endoglin modulation of TGF-β1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem. 2006;18:135–142.[PubMed][Google Scholar]
23. Garcia-Pozo L, Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Monzon CEndoglin: structure, biologcial functions and role in fibrogenesis. Rev Esp Enferm Dig. 2008;100:355–360.[PubMed][Google Scholar]
24. Rodriguez-Pena A, Eleno N, Duwell A, et al Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension. 2002;40:713–720.[PubMed][Google Scholar]
25. Weber KTExtracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065–4082.[PubMed][Google Scholar]
26. Weber KT, Brilla CGPathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system. Circulation. 1991;83:1849–1865.[PubMed][Google Scholar]
27. Wu L, Iwai M, Nakagani H, et al Effect of angiotensin type 1 receptors blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arterioscler Thromb Vasc Biol. 2002;22:49–54.[PubMed][Google Scholar]
28. Sui Y, Zhang JQ, Zhang J, Ramires JAngiotensin II, transforming growth factor-beta 1 and repair the infarcted heart. J Mol Cell Cardiol. 1998;30:1559–1569.[PubMed][Google Scholar]
29. Chung CC, Kao YH, Liou JP, Chen YICurcumin suppress cardiac fibroblasts activities by regulating proliferation, migration, and the extracellular matrix. Acta Cardiol Sin. 2014;30:474–482.[Google Scholar]
30. Shyu KG, Wang BW, Chen WJ, et al Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta 1 in cultured cardiac fibroblasts. Eur J Heart Fail. 2010;12:219–226.[PubMed][Google Scholar]
31. Pospisilova N, Semeeky V, Jamborova G, et al Endoglin expression in hypercholesterolemia and after atorvastatin treatment in apo-E deficient mice. J Pharm Pharmaceut Sci. 2006;9:388–397.[PubMed][Google Scholar]
32. Nachtigal P, Pospisilova N, Jamborova G, et al Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Can J Physiol Pharmacol. 2007;85:767–773.[PubMed][Google Scholar]
33. Torsoni AS, Constancio SS, Nadruz W, et al Focal adhesion kinase is activated and mediates the early hypertrophic response to stretch in cardiac myocytes. Circ Res. 2003;93:140–147.[PubMed][Google Scholar]
34. Shyu KG, Wang BW, Wu GJ, et al Mechanical stretch via transforming growth factor-β1 activates microRNA208a to regulate endoglin expression in cultured rat cardiac myoblasts. Eur J Heart Fail. 2013;15:36–45.[PubMed][Google Scholar]
35. Wang BW, Wu GJ, Cheng WP, Shyu KGMechanical stretch via transforming growth factor-β1 activates micro-RNA-208a to regulate hypertrophy in cultured rat cardiac myocytes. J Formos Med Assoc. 2013;112:635–643.[PubMed][Google Scholar]
36. Wang BW, Wu GJ, Cheng WP, Shyu KGMicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. Plos One. 2014;9:e84188.[Google Scholar]
37. Bartel DPMicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.[PubMed][Google Scholar]
38. Place RF, Li LC, Pookot D, et al MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA. 2008;105:1608–1613.[Google Scholar]
39. Kapur NK, Qiao X, Paruchuri V, et al Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload. J Am Heart Assoc. 2014;3:e000965.[Google Scholar]
40. Shyu KG, Wang BW, Cheng WP, Lo HMMicroRNA-208a increases myocardial endoglin expression and myocardial fibrosis in acute myocardial infarction. Can J Cardiol. 2015;31:679–690.[PubMed][Google Scholar]
41. Lin CM, Chang H, Wang BW, Shyu KGSuppressive effect of epigallocatechin-3-O-gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo. J Cell Mol Med. 2016;20:2045–2055.[Google Scholar]
42. Tseliou E, Reich H, de Couto G, et al Cardiospheres reverse adverse remodeling in chronic myocardial infarction: roles of soluble endoglin and TGF-β signaling. Basic Res Cardiol. 2014;109:443–455.[PubMed][Google Scholar]
43. Kapur NK, Hefferman KS, Yunis AA, et al Usefulness of soluble endoglin as a non-invasive measure of left ventricular filling pressure in heart failure. Am J Cardiol. 2010;106:1770–1776.[Google Scholar]
44. Yanavitski M, Givertz MMNovel biomarkers in acute heart failure. Curr Heart Fail Rep. 2011;8:206–211.[PubMed][Google Scholar]
45. Ikemoto T, Hojo Y, Kondo H, et al Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012;27:344–351.[PubMed][Google Scholar]
46. Wang CC, Chang HY, Yin WH, et al TSOC-HFrEF registry: a registry of hospitalized patients with decompensated systolic heart failure: description of population and management. Acta Cardiol Sin. 2016;32:400–411.[Google Scholar]